Literature DB >> 29135821

Compliance With Fecal Calprotectin Testing in Pediatric Patients With Inflammatory Bowel Disease.

Karen Queliza1, Michael K Wang1, Richard Kellermayer1,2.   

Abstract

Fecal calprotectin (FC) is a highly sensitive biomarker for inflammatory bowel diseases (IBDs). Utilization of this assay has been steadily increasing. Adherence levels for FC have, however, yet to be examined in the pediatric IBD setting. We analyzed 100 consecutive patients diagnosed with IBD between 2014 and 2015 at Texas Children's Hospital. Fifty-six percent of patients were men and median age at diagnosis was 13.7 years. Following diagnosis of IBD, 84 patients had a minimum of 1 FC requested, and 95.2% of these patients completed the test at least once. An average of 2 FCs per patient was ordered each year, and the overall compliance was 76.6%. Patients who completed the initial testing with a minimum of 3 consecutive tests were more likely to remain compliant than those who failed to perform the first lab (P < 0.001). Our findings indicate good compliance with FC testing in pediatric patients with IBD.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29135821     DOI: 10.1097/MPG.0000000000001837

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  1 in total

1.  Validation of the newly FDA-approved Buhlmann fCal Turbo assay for measurement of fecal calprotectin in a pediatric population.

Authors:  Emily Garnett; Jayson Pagaduan; Deepthi Rajapakshe; Estella Tam; Richard Kellermayer; Sridevi Devaraj
Journal:  Pract Lab Med       Date:  2020-10-17
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.